*3.2. HPV Positivity and Genotype Distribution among Samples Collected*

HPV positivity results considering and not considering the clinical cut-off are reported in Figure 1. A very high rate of HPV positivity in cervical samples was found among the women enrolled: 67.2% (43/64) and 73.4% (47/64) considering and not considering the clinical cut-off, respectively. Considering just results obtained regarding HPV genotypes individually detected, HPV 16 was the most prevalent genotype identified among samples analysed, followed by HPV 31. Using the clinical cut-off, multiple genotype infections were observed in 14% (9/64), 18.7% (12/64), and 21.8% (14/64) of cervical, vaginal, and urine samples, respectively. Not considering the clinical cut-off, the percentages obtained were 31.2% (20/64), 28.1% (18/64), and 35.9% (23/64) for cervical, vaginal, and urine samples, respectively (Figure 2).

vaginal, and urine samples, respectively (Figure 2).

vaginal, and urine samples, respectively (Figure 2).

*Diagnostics* **2022**, *12*, x FOR PEER REVIEW 5 of 11

percentages obtained were 31.2% (20/64), 28.1% (18/64), and 35.9% (23/64) for cervical,

percentages obtained were 31.2% (20/64), 28.1% (18/64), and 35.9% (23/64) for cervical,

**Figure 1.** HPV positivity analysed considering and not considering clinical cut-off. **Figure 1.** HPV positivity analysed considering and not considering clinical cut-off. **Figure 1.** HPV positivity analysed considering and not considering clinical cut-off.

**Figure 2.** HPV genotype distribution analysed considering and not considering clinical cut-off. **Figure 2.** HPV genotype distribution analysed considering and not considering clinical cut-off. **Figure 2.** HPV genotype distribution analysed considering and not considering clinical cut-off.
